英特格拉生命科學 IART 深 滬
等待開盤 11-04 09:30:00 美东时间
13.63
+0.020
+0.15%
華盛通- 最 高13.79
- 今 開13.69
- 成交量 169.34万股
- 最 低 13.40
- 昨 收 13.61
- 總市值 10.60亿
- 52周最高 20.49
- 市盈率 靜 --
- 換手率 2.18%
- 52周最低 8.70
- 委 比 -26.20%
- 總股本 7780.10万
- 歷史最高 77.40
- 量 比 1.22
- 振 幅 2.87%
- 歷史最低 8.70
- 每 手 1
- 風險率 2.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多英特格拉生命科学收涨6.75%，成交额2056.28万美元
11月3日，英特格拉生命科学（IART）收涨6.75%，报13.61美元，成交额2056.28万美元，市值10.58亿美元。 行情数据 • 开盘价：12.98美...
11-03 06:43
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
Integra LifeSciences will participate in the 2026 CNS Annual Meeting in Washington, D.C., showcasing its neurosurgery portfolio, including the Aurora® Surgiscope® System, DuraGen®, Durepair®, and CUSA® Clarity. Attendees can engage in hands-on training and interactive experiences at Booth 341 and participate in the CNS Skills Showdown. Integra emphasizes innovation and collaboration to improve patient care, with a focus on neurocritical care, dur...
10-30 12:30
英特格拉生命科学收跌3.37%，成交额1449.65万美元
10月24日，英特格拉生命科学（IART）收跌3.37%，报11.91美元，成交额1449.65万美元，市值9.26亿美元。 行情数据 • 开盘价：12.12美...
10-24 05:49
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
10-22 21:59
Integra LifeSciences' $2.1B Refinancing Merits A Closer Look
Integra LifeSciences Holdings Corporation (NASDAQ:IART) completed a $2.1 billion refinancing on October 19, 2026. Its revolving credit commitment fell $700 million, from $1.3 billion to $600 million, while the new bank agreement schedules $52.5 million of term-loan principal installments during 2027...
10-22 18:28
Integra Lifesciences Q3 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $411.182M Miss $414.120M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 9.26 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $411.182 mill...
10-21 18:02
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634 billion-$1.654 billion vs $1.661 billion estimate.
10-21 18:01
Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.61-$0.71 vs $0.76 analyst estimate. sees sales of $413.000 million-$433.000 million vs $436.772 million analyst estimate.
10-21 18:01
Integra Announces Completion of Refinancing Transactions
Integra LifeSciences Holdings Corporation announced the completion of a $450 million private offering of 9.500% senior secured notes due 2033 and the amendment of its $1.65 billion credit facility. The funds will be used to refinance existing debt and cover related expenses. The notes are senior secured obligations and were offered to qualified institutional buyers and certain non-U.S. investors under specific regulations. This press release is n...
10-19 20:05
